Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1260

Sort by

Sort Order Select

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency

Blood (2019) 134 (Supplement_1): 608.

https://doi.org/10.1182/blood-2019-127439

Published: 2019

Journal Articles

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Eftathios Kastritis, Maria Gavriatopoulou, MD, Maria Roussou, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioanna Dialoupi, MD, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Foteini Theodorakakou, MD, Asimina Papanikolaou, MD, Erasmia Psimenou, MD, Kimon Stamatelopoulos, MD, Efstathios Manios, MD, Maria Irini Tselegkidi, MD, Argyrios Ntalianis, MD, Stavroula Giannouli, MD PhD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1894.

https://doi.org/10.1182/blood-2019-128208

Published: 2019

Journal Articles

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Safaa M. Ramadan, PhD MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Enrico Derenzini, MD PhD, Giusy Ceparano, MD, Tommaso Radice, MD, Federica Gigli, MD, Stefano Fiori, MD, Valentina Tabanelli, MD, Martina Milani, Emanuela Omodeo Sale', Sara Gandini, PhD, Daniela Gottardi, MD, Giuseppe Saglio, MD, Stefano Pileri, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1631.

https://doi.org/10.1182/blood-2019-128794

Published: 2019

Journal Articles

Early Discontinuation (ED) of Therapy and Treatment Patterns Among Chronic Lymphocytic Leukemia (CLL) Patients: Findings from a Linked Claims and Electronic Health Record (EHR) Dataset

Seth Kuranz, MPH, Jennifer Stacey, BS, Sierra Luciano, BS

Blood (2019) 134 (Supplement_1): 1749.

https://doi.org/10.1182/blood-2019-130848

Published: 2019

Journal Articles

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Zheng Wei, MD, Yian Zhang, Jing Li, MD, Peng Liu, MD

Blood (2019) 134 (Supplement_1): 1908.

https://doi.org/10.1182/blood-2019-127023

Published: 2019

Journal Articles

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Blood (2019) 134 (Supplement_1): 1949.

https://doi.org/10.1182/blood-2019-131546

Published: 2019

Journal Articles

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

Bernhard Gentner, MD, Francesca Farina, MD, Matteo Giovanni Carrabba, MD, Magda Marcatti, MD, Stefania Girlanda, MD, Gabriele Antonarelli, MD, Capotondo Alessia, PhD, Stefania Mazzoleni, PhD, Carlo Russo, MD, Luigi Naldini, MD PhD, Fabio Ciceri, MD

Blood (2019) 134 (Supplement_1): 2064.

https://doi.org/10.1182/blood-2019-123749

Published: 2019

Journal Articles

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 2025.

https://doi.org/10.1182/blood-2019-130786

Published: 2019

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 2027.

https://doi.org/10.1182/blood-2019-131818

Published: 2019

Journal Articles

Overall Survival in Patients with Myelofibrosis Who Have Discontinued Ruxolitinib: A Literature Review

Derek Tang, PhD BSPharm, Ankush Taneja, Preety Rajora, Indeg Sly, Niall James Davison

Blood (2019) 134 (Supplement_1): 3457.

https://doi.org/10.1182/blood-2019-122904

Published: 2019

Journal Articles

No Improvement in Survival for T-PLL Patients over the Last Two Decades

Matthew J Cross, MBBS, BSc, Monica Else, Ricardo Morilla, Mark Edward Ethell, MD, Michael Potter, MD, Dima El-Sharkawi, Sunil Iyengar, MBBS, FRCPath, PhD, Claire E. Dearden, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 1552.

https://doi.org/10.1182/blood-2019-122094

Published: 2019

Journal Articles

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure

Blood (2019) 134 (Supplement_1): 1554.

https://doi.org/10.1182/blood-2019-129199

Published: 2019

Journal Articles

Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling

Blood (2019) 134 (Supplement_1): 1497.

https://doi.org/10.1182/blood-2019-131072

Published: 2019

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Journal Articles

AML: Negative Prognostic Impact of Early Blast Persistence Can be Overcome By Subsequent Remission Induction

Jana Ihlow, MD, Sophia Gross, Leonie Busack, Alma Herneth, Igor-Wolfgang Blau, MD PhD, Ioannis Anagnostopoulos, MD, Michaela Schwarz, MD, Anne Floercken, MD, Lars Bullinger, MD, Jörg Westermann, MD

Blood (2019) 134 (Supplement_1): 1324.

https://doi.org/10.1182/blood-2019-127174

Published: 2019

Journal Articles

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hannah Asghari, MD BS, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 1357.

https://doi.org/10.1182/blood-2019-128958

Published: 2019

Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Blood (2019) 134 (Supplement_1): 1589.

https://doi.org/10.1182/blood-2019-123637

Published: 2019

Journal Articles

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Weiguo Zhang, MD PhD, Richard Graydon, MD PhD, Vikas K Dawra, MBA, PhD, Jingdong Xie, PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1389.

https://doi.org/10.1182/blood-2019-122585

Published: 2019

NARROW

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Early Discontinuation (ED) of Therapy and Treatment Patterns Among Chronic Lymphocytic Leukemia (CLL) Patients: Findings from a Linked Claims and Electronic Health Record (EHR) Dataset

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Overall Survival in Patients with Myelofibrosis Who Have Discontinued Ruxolitinib: A Literature Review

No Improvement in Survival for T-PLL Patients over the Last Two Decades

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure

Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

AML: Negative Prognostic Impact of Early Blast Persistence Can be Overcome By Subsequent Remission Induction

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only